Efferalgan med Paracetamol 16 Effervescent Tablets 500 mg

Efferalgan med Paracetamol 16 Effervescent Tablets 500 mg

GENERAL PHARMA SOLUTIONS

SKU
044695017
Special Price €6.24 Regular Price €6.90 Save... €0.66 -10%
Recent lowest price:   €6.14
In stock
icomoon-up
icomoon-down
NAME
EFFERALGAN 500 mg effervescent tablets

PHARMACOTHERAPEUTIC CATEGORY
Analgesics and antipyretics.

ACTIVE PRINCIPLES < / b>
Paracetamol 500 mg.

EXCIPIENTS
Citric acid, sodium carbonate, sodium bicarbonate, sorbitol, sodium saccharinate, sodium docusate, povidone, sodium benzoate. < br>
INDICATIONS
Symptomatic treatment of mild to moderate pain and febrile conditions in adults and children. Symptomatic treatment of arthritic pain.

CONTRAINDICATIONS / EFF.SECONDAR
Hypersensitivity to paracetamol or propacetamol hydrochloride (precursor of paracetamol) or to any of the excipients.

DOSAGE
Oral use. Dissolve the tablet completely in a glass of water. The medicine is reserved for adults and children weighing more than 13 kg (about 2 years). In children, dosage regimens based on body weight must be respected and therefore it is necessary to choose the appropriate formulation. The correspondence between age and weight is only indicative. Children weighing between 13 kg and 20 kg (age between 2 and 7 years approximately): half tablet each administration, to be repeated, if necessary, after an interval of at least 6 hours, without exceeding 3 half tablets per day for children weighing less than 15 kg and 4 half tablets per day for children weighing 15 kg or more. Children weighing between 21 kg and 25 kg (age between about 6 and 10 years): half tablet each administration, to be repeated, if necessary, after an interval of at least 6 hours, without exceeding 5 half tablets a day for children weighing less than 25 kg and 6 half tablets per day for children weighing 25 kg or more. Children weighing between 26 kg and 40 kg (age between 8 and 13 years approximately): 1 tablet each administration, to be repeated, if necessary, after an interval of at least 6 hours, without exceeding 4 tablets per day. Adolescents with a body weight between 41 kg and 50 kg (age between 12 and 15 years approximately): 1 tablet each administration, to be repeated, if necessary, after an interval of at least 4 hours without exceeding 6 tablets per day. Adults and adolescents weighing more than 50 kg (about 15 years or more): the usual unit dosage is one tablet for each administration, to be repeated, if necessary, after an interval of at least 4 hours. 3 g of paracetamol per day, or 6 tablets per day, should not be exceeded, respecting an interval of at least 4 hours between administrations. Adults: in case of more intense pain, two tablets can be taken at a time for a maximum of 3 times a day (3 g of paracetamol), always respecting an interval of at least 4 hours between doses. Frequency of administration: Regular administration avoids fluctuating pain or fever levels. In children, the interval between administrations should be regular, both day and night, and should preferably be at least 6 hours. In adults and adolescents, an interval of at least 4 hours between administrations must always be respected. Renal insufficiency: in case of severe renal insufficiency (creatinine clearance less than 10 ml / min), the interval between dosing should be at least 8 hours. Do not exceed 3 g of paracetamol per day, i.e. 6 tablets. In adults and adolescents of body weight over 40 kg, the total dosage of paracetamol should not exceed 3 g / day.

STORAGE
This medicine does not require any special conditions of preservation.

WARNINGS
Paracetamol should be administered with caution to patients with mild to moderate hepatic insufficiency (including Gilbert's syndrome), severe hepatic insufficiency (Child-Pugh> 9), acute hepatitis, in concomitant treatment with drugs that alter liver function, glucose-6-phosphate-dehydrogenase deficiency, haemolytic anemia. Do not administer during chronic treatment with drugs that can determine the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect. Paracetamol should be administered with caution in subjects with renal insufficiency (Clcr <= 30 ml / min). Use with caution in case of chronic alcoholism, excessive alcohol intake (3 or more alcoholic drinks per day), anorexia, bulimia or cachexia, chronic malnutrition (low reserves of hepatic glutathione), dehydration, hypovolemia. During treatment with paracetamol, before taking any other drug, check that it does not contain the same active ingredient, as if paracetamol is taken in high doses, serious adverse reactions can occur. High or prolonged doses of the product can cause high-risk liver disease and alterations, even serious ones, in the kidney and blood. In case of prolonged use it is advisable to monitor liver and kidney function and blood count. In the event of an allergic reaction, the administration should be suspended. This medicinal product contains 412.4 mg of sodium (equivalent to 18 mEq) per tablet. To be considered for administration in patients with impaired renal function or who follow a low sodium diet. It also contains sorbitol: use with caution in patients with rare hereditary problems of fructose intolerance.

INTERACTIONS
Paracetamol can increase the possibility of effects undesirable if administered simultaneously with other drugs.The administration of paracetamol can interfere with the determination of uric acid (by the method of phosphotungstic acid) and with that of glycaemia (by the method of glucose-oxidase-peroxidase). During therapy with oral anticoagulants it is recommended to reduce the doses. Monooxygenase-inducing drugs: use with extreme caution and under strict control during chronic treatment with drugs that can determine the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (e.g. rifampicin, cimetidine, antiepileptics such as glutethimide , phenobarbital, carbamazepine). Phenytoin: concomitant administration of phenytoin may result in decreased efficacy of paracetamol and in an increased risk of hepatotoxicity. Patients treated with phenytoin should avoid high and / or chronic doses of paracetamol. Patients should be monitored for evidence of hepatotoxicity. Probenecid: This causes an at least two-fold reduction in the clearance of paracetamol through the inhibition of its conjugation with glucuronic acid. A reduction in the dose of paracetamol when administered concomitantly with probenecid should be considered. Salicylamide: may prolong the elimination half-life (t1 / 2) of paracetamol.

UNDESIRABLE EFFECTS
Skin reactions of various types and severity have been reported including erythema multiforme, Stevens-Johnson syndrome and epidermal necrolysis. Hypersensitivity reactions have been reported such as angioedema, larynx edema, anaphylactic shock. In addition, the following undesirable effects have been reported: thrombocytopenia, leukopenia, anemia, agranulocytosis, liver function abnormalities and hepatitis, kidney disorders (acute renal failure, interstitial nephritis, haematuria, anuria), gastrointestinal reactions and dizziness. Post-marketing: the frequency of reported adverse reactions is not known. Alterations of the blood and lymphatic system: thrombocytopenia, neutropenia, leukopenia. Alterations of the gastrointestinal system: diarrhea, abdominal pain. Alterations of the hepatobiliary system: increase in liver enzymes. Alterations of the immune system: anaphylactic shock, Quincke's edema, hypersensitivity reactions. Diagnostic investigations: decrease in INR values, increase in INR values. Skin and subcutaneous tissue alterations: urticaria, erythema, rash. Alterations of the vascular system: hypotension (as a symptom of anaphylaxis). In case of overdose, paracetamol can cause hepatic cytolysis which can evolve towards massive and irreversible necrosis.

PREGNANCY AND LACTATION
Clinical experience with use of paracetamol during pregnancy and lactation is limited. Epidemiological data on the use of therapeutic doses of oral paracetamol indicate that no adverse effects occur in pregnant women or on the health of the fetus or newborn babies. Reproductive studies with paracetamol did not reveal any malformation or foetotoxic effects. However, paracetamol should only be used during pregnancy after a careful evaluation of the risk / benefit ratio. In pregnant patients, the recommended posology and duration of treatment should be strictly observed. Breastfeeding: paracetamol is excreted in small quantities in breast milk. Rash has been reported in breast-fed infants. However, the administration of paracetamol is considered compatible with breastfeeding. However, caution should be exercised in administering paracetamol to breastfeeding women.
Destination Cost Detail
Italy €5,90 24/48 h
Austria, Belgium, France, Germany, Netherlands, Poland, Czech Republic € 12* 3 days
Denmark,Luxembourg,Portugal,Slovakia,Spain,Hungary € 16* 4 days
Bulgary,Croatia,Estonia,Finland,Greece,Ireland,Lithuania,Romania,Slovenia,Sweden € 27* 5 days
Canada, Switzerland, United Kingdom, USA € 45 7 Days

National shipments with express courier: Bartolini, GLS
European shipments with express courier: FedEx, MBE, DHL
*For the shipment outside band B ther's an extra cost of 20€
*For the shipment outside band C ther's an extra cost of 30€
Delivery Times exclude Saturday and Holidays
For Islands and Areas of difficult Accessibility the shipments are made in 72 hours and the cost will be increased by 15€
The images of the products shown on our site are purely indicative and may differ in shape, color, text and packaging shown on them. Given the difficulty of updating all the products on our site in real time or any errors, XFarma.it, all products will be identified through SKU MINSAN (code of the Ministry of Health).